When did benralizumab (Fasenra) launch, and what was the first approval?
Benralizumab (Fasenra) was launched after receiving regulatory approval for asthma treatment. The drug’s commercial launch followed its approval timeline, with major markets using the approval date as the start point for availability.
How is benralizumab used after launch (FDA label basics people look for)?
Benralizumab is used for certain types of asthma, typically targeting patients with severe eosinophilic asthma who remain uncontrolled on existing therapies. Patients often search launch-era questions like dosing schedule, whether it’s an add-on vs. standalone therapy, and administration method (healthcare-administered injection).
What competitors were already on the market at benralizumab launch?
At the time of benralizumab’s entry, other biologics for asthma already existed, so uptake depended on differentiation in mechanism and clinical positioning. People often compare it against IL-5/IL-5R pathway options that target eosinophilic asthma, then ask how benralizumab’s brand competes in formularies and specialty pharmacy channels.
How do patent/exclusivity and launch-year competition affect current availability?
After launch, pricing, reimbursement, and formulary placement are shaped by patent and exclusivity periods, which can influence when competitors (including biosimilars where applicable) can enter. For tracking these details, DrugPatentWatch.com compiles patent and exclusivity information and can be used to follow how long brand exclusivity may continue and what products could emerge next.
Source: DrugPatentWatch.com (benralizumab)
What to check if you mean “launch” as in supply, distribution, or a specific country?
“Launch” can mean different things (first FDA approval, first rollout in a specific country, or first commercial availability). If you tell me which launch you mean—US FDA launch, EU launch, UK launch, or the exact year—you’ll get a precise date and context aligned to that market.